NuvOx Pharma, a Tucson-based biotechnology company developing NanO2 emulsion for oxygen delivery, has received a “No Objection Letter” from Health Canada to proceed with a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF).
Theravance Biopharma has dosed the first patient in the phase 2 study of lung-selective and nebulized Janus kinase inhibitor (JAKi) TD-0903 to treat hospitalised patients with acute lung injury (ALI) due to Covid-19.
Noxopharm has launched a clinical programme, called NOXCOVID, for its Covid-19 drug candidate Veyonda by starting a phase 1 trial in Europe.
METTLER TOLEDO follows in the tradition of INGOLD by continuing to provide innovative new products and systems based on decades of accumulated knowledge and experience in industrial measurement technology.
Full results from the positive Phase III ETHOS trial showed AstraZeneca’s triple-combination therapy PT010 (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Novaremed, a clinical-stage Swiss biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to initiate its US-based Phase 2 clinical study of the novel drug candidate, NRD135S.E1, for the treatment of Painful Diabetic Peripheral Neuropathy (PDPN).
Merck said that V114, its investigational 15-valent pneumococcal conjugate vaccine candidate, has met safety and immunogenicity goals in two initial phase 3 trials in adults.
After transferring the media slurry into the open column, the piston is quickly mounted in a way that avoids air entry, and the column is sealed.
Roche announced that Tecentriq (atezolizumab) plus chemotherapy has achieved primary endpoint in the trial of patients with triple-negative breast cancer (TNBC).
Merck, known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced the presentation of results from the Phase 3 VERTIS CV cardiovascular (CV) outcomes trial that evaluated STEGLATRO (ertugliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, versus placebo, added to background standard of care treatment, in more than 8,200 patients with type 2 diabetes and atherosclerotic CV disease across 531 centers in 34 countries.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.